NCT01508156View on ClinicalTrials.gov

Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Hepatitis C, Chronic

Interventions

DRUG

IDX719

IDX719 liquid suspension (1 - 100 mg) taken by mouth.

DRUG

Placebo

Placebo liquid suspension matching IDX719 taken by mouth.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01508156 - Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001) | Biotech Hunter | Biotech Hunter